Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

Research output: Contribution to journalJournal articleResearchpeer-review


  1. ACE genotype, phenotype and all-cause mortality in different cohorts of patients with type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Renin-angiotensin-aldosterone system (RAAS) blockade may reduce levels of biomarkers of chronic low-grade inflammation and endothelial dysfunction. We investigated the effect of spironolactone added to standard RAAS blockade on these biomarkers in an analysis of four original studies. MATERIALS AND METHODS: The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days.Outcome measures:Changes in inflammatory (hsCRP, s-ICAM, TNFα, IL-6, IL-8, Serum amyloid A, IL1β), endothelial dysfunction (sE-selectin, s-ICAM1, s-VCAM1, VWF, p-selectin, s-thrombomodulin) and NT-proBNP after each treatment period. RESULTS: During spironolactone treatment, u-albumin excretion rate was reduced from 605 (411-890) to 433 (295-636) mg/24 h, as previously reported. Markers of inflammation and endothelial dysfunction did not change; only changes in NT-proBNP (reduced by 14%, p=0.05) and serum amyloid A (reduced by 62%, p=0.10) were borderline significant.Discussions:Our results indicate that the renoprotective effect of spironolactone when added to RAAS blockade is not mediated through anti-inflammatory pathways since markers of inflammation and endothelial dysfunction are not affected during treatment.
Original languageEnglish
JournalJournal of the Renin-Angiotensin-Aldosterone System
Issue number2
Pages (from-to)161-6
Publication statusPublished - 2013

ID: 36877989